Opus Genetics Inc. Ordinary Shares IRD 深 滬
已收盤 09-19 16:00:00 美东时间
1.52
+0.030
+2.01%
華盛通- 最 高1.59
- 今 開1.50
- 成交量 87.00万股
- 最 低 1.4207
- 昨 收 1.49
- 總市值 9106.03万
- 52周最高 1.75
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.65
- 委 比 -37.95%
- 總股本 5990.81万
- 歷史最高 23.08
- 量 比 3.40
- 振 幅 11.36%
- 歷史最低 0.65
- 每 手 1
- 風險率 0.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ASHFORD TRUST SETS THIRD QUARTER EARNINGS RELEASE AND CONFERENCE CALL DATES
DALLAS, Sept. 17, 2025 /PRNewswire/ -- Ashford Hospitality Trust, Inc. (NYSE: AHT) ("Ashford Trust" or the "Company") today announced details for the release of its results for the third qua...
09-17 22:00
Opus Genetics Announces First Patient Has Been Dosed In Its Phase 3 Lynx-3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% For Treating Chronic Night Driving Impairment In Keratorefractive Patients With Reduced Mesopic Vision
Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic disorders, today announced
09-04 20:14
Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September
Opus Genetics, a biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs), announced its participation in several scientific conferences in September 2025 to present its IRD gene therapy programs. Key presentations include discussions on gene therapies for retinal diseases at the Ophthalmology Futures Forum in Paris, updates on a Phase I/II study of OPGx-LCA5 at the RD 2025 Symposium in Prague, and a panel discuss...
08-27 12:00
VERSABANK TO HOST THIRD QUARTER FISCAL 2025 FINANCIAL RESULTS CONFERENCE CALL/WEBCAST
Bank to Report Third Quarter Fiscal 2025 Results Thursday, September 4, 2025 at 7:00 a.m. ET LONDON, ON, Aug. 21, 2025 /PRNewswire/ - VersaBank ("VersaBank" or the "Bank") (TSX: VBNK) (NASDA...
08-21 19:00
Leon Cooperman, David Tepper Beat Warren Buffett, Bill Ackman In Q2 Billionaire Face-Off
Q2 delivered a jolt for hedge fund watchers, with some of Wall Street's most storied managers posting eye-catching gains.
08-19 00:45
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
Opus Genetics announced FDA acceptance of its IND application for OPGx-BEST1, a gene therapy targeting BEST1-related inherited retinal diseases. A Phase 1/2 trial is planned for second half 2025 to assess safety, tolerability, and efficacy in patients with BEST1-related IRD. This marks the company's third clinical program, reflecting its commitment to advancing therapies for unmet needs in vision loss. CEO George Magrath highlighted the significa...
08-18 12:00
Deere Reports Third Quarter Net Income of $1.289 Billion
Disciplined execution yields solid results in the face of a challenging environment. Customers remain cautious amid ongoing uncertainty. Full-year net income guidance narrowed. MOLINE, Ill.,...
08-14 18:27
Opus Genetics Q2 EPS $(0.12) Beats $(0.20) Estimate, Sales $2.88M Miss $4.04M Estimate
Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.20) by 41.46 percent. The company reported quarterly sales of $2.88 million which missed the
08-14 04:35
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
Opus Genetics announced positive clinical data and regulatory progress for its gene therapy programs, including RMAT designation for OPGx-LCA5 and positive topline results for Phentolamine Ophthalmic Solution. The company reported $32.4 million in cash and a net loss of $7.4 million for Q2 2025. --- Opus Genetics reported financial results for Q2 2025, noting $32.4 million in cash and a net loss of $7.4 million. Key updates include FDA RMAT de...
08-13 20:30
